All Stories

  1. Demographic and clinical characteristics of patients with α1-antitrypsin deficiency genotypes PI*ZZ and PI*SZ in the Spanish registry of EARCO
  2. Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews
  3. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD
  4. Research priorities in α1-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration
  5. Prevalence of α1-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review
  6. Withdrawal of inhaled corticosteroids in COPD
  7. Preventing readmissions of COPD patients: more prospective studies are needed
  8. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline
  9. The right treatment for the right patient with COPD: lessons from the IMPACT trial
  10. Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?
  11. Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients
  12. Time To Revise COPD Treatment Algorithm
  13. Comparison of clinical baseline characteristics between Asian and Western COPD patients in a prospective, international, multicenter study
  14. Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms
  15. Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps
  16. External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study
  17. Practical Guide to the Identification and Diagnosis of Asthma-COPD Overlap (ACO)
  18. The European Alpha-1 Research Collaboration (EARCO): a new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency
  19. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study [Corrigendum]
  20. Bronchiectasis in COPD patients: more than a comorbidity? [Corrigendum]
  21. Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research – a consensus document from six scientific societies [Corrigendum]
  22. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment [Corrigendum]
  23. Joint statement for the diagnosis, management, and prevention of chronic obstructive pulmonary disease for Gulf Cooperation Council countries and Middle East-North Africa region, 2017 [Corrigendum]
  24. Validation of clinical control in COPD as a new tool for optimizing treatment
  25. Evaluating the impact of morning symptoms in COPD using the Capacity of Daily Living during the Morning (CDLM) questionnaire
  26. Geographical Distribution of COPD Prevalence in the Americas
  27. How whole-body vibration can help our COPD patients. Physiological changes at different vibration frequencies
  28. Prevalence of smoking in a psychiatric hospital and its relationship with respiratory symptoms and the prevalence of COPD
  29. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study
  30. Depressive status explains a significant amount of the variance in COPD assessment test (CAT) scores
  31. Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT)
  32. New era for European Respiratory Society clinical practice guidelines: joining efficiency and high methodological standards
  33. Mixed Th2 and non-Th2 inflammatory pattern in the asthma–COPD overlap: a network approach
  34. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment
  35. Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique
  36. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial
  37. Gene and miRNA expression profiles in PBMCs from patients with severe and mild emphysema and PiZZ alpha1-antitrypsin deficiency
  38. Impact and prevention of severe exacerbations of COPD: a review of the evidence
  39. Joint statement for the diagnosis, management, and prevention of chronic obstructive pulmonary disease for Gulf Cooperation Council countries and Middle East–North Africa region, 2017
  40. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
  41. Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD Guidelines: the FENEPOC study
  42. Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research – a consensus document from six scientific societies
  43. Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide
  44. Palliative care and prognosis in COPD: a systematic review with a validation cohort
  45. Algorithm for identification of asthma–COPD overlap: consensus between the Spanish COPD and asthma guidelines
  46. Diagnosis of asthma–COPD overlap: the five commandments
  47. Bronchiectasis in COPD patients: more than a comorbidity?
  48. Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study
  49. Self-reported daily walking time in COPD: relationship with relevant clinical and functional characteristics
  50. Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study
  51. Pathophysiology of dyspnea in COPD
  52. New guidelines for treatment and management of COPD exacerbations
  53. A new two-step algorithm for the treatment of COPD
  54. Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update
  55. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
  56. Diagnosis of alpha-1 antitrypsin deficiency: a population-based study
  57. Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation
  58. Cognitive status among patients with chronic obstructive pulmonary disease
  59. A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD
  60. A review of national guidelines for management of COPD in Europe
  61. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients
  62. Efficacy of augmentation therapy for emphysema associated with α1-antitrypsin deficiency: enough is enough
  63. The chronic obstructive pulmonary disease assessment test improves the predictive value of previous exacerbations for poor outcomes in COPD
  64. Is a previous diagnosis of asthma a reliable criterion for asthma–COPD overlap syndrome in a patient with COPD?
  65. de Torres JP
  66. Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease
  67. Caregivers’ burden in patients with COPD
  68. Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease
  69. The concept of control of COPD in clinical practice
  70. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns
  71. The Spectrum of Bronchial Infection
  72. Introduction
  73. Modifying the clinical course of COPD
  74. Chronic obstructive pulmonary disease: the exacerbation
  75. Enfermedad pulmonar obstructiva crónica